ALAUNOS THERAPEUTICS INC (TCRT) Stock Price & Overview
NASDAQ:TCRT • US98973P3091
Current stock price
The current stock price of TCRT is 2.84 USD. Today TCRT is down by -2.74%. In the past month the price decreased by -11.8%. In the past year, price increased by 7.98%.
TCRT Key Statistics
- Market Cap
- 6.759M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.21
- Dividend Yield
- N/A
TCRT Stock Performance
TCRT Stock Chart
TCRT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TCRT. When comparing the yearly performance of all stocks, TCRT turns out to be only a medium performer in the overall market: it outperformed 42.18% of all stocks.
TCRT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRT. While TCRT seems to be doing ok healthwise, there are quite some concerns on its profitability.
TCRT Earnings
TCRT Forecast & Estimates
For the next year, analysts expect an EPS growth of -116.28% and a revenue growth -100% for TCRT
TCRT Groups
Sector & Classification
TCRT Financial Highlights
Over the last trailing twelve months TCRT reported a non-GAAP Earnings per Share(EPS) of -2.21. The EPS decreased by -11.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -140.8% | ||
| ROE | -193.96% | ||
| Debt/Equity | 0 |
TCRT Ownership
TCRT Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.74 | 360.314B | ||
| AMGN | AMGEN INC | 15.33 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.55 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.37 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCRT
Company Profile
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
Company Info
IPO: 2004-08-20
ALAUNOS THERAPEUTICS INC
501 E Las Olas Blvd, Suite 300
FORT LAUDERDALE FLORIDA US
Employees: 1
Phone: 13463554099
ALAUNOS THERAPEUTICS INC / TCRT FAQ
What does ALAUNOS THERAPEUTICS INC do?
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.
Can you provide the latest stock price for ALAUNOS THERAPEUTICS INC?
The current stock price of TCRT is 2.84 USD. The price decreased by -2.74% in the last trading session.
Does ALAUNOS THERAPEUTICS INC pay dividends?
TCRT does not pay a dividend.
How is the ChartMill rating for ALAUNOS THERAPEUTICS INC?
TCRT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy TCRT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TCRT.
Can you provide the market cap for ALAUNOS THERAPEUTICS INC?
ALAUNOS THERAPEUTICS INC (TCRT) has a market capitalization of 6.76M USD. This makes TCRT a Nano Cap stock.
When does ALAUNOS THERAPEUTICS INC (TCRT) report earnings?
ALAUNOS THERAPEUTICS INC (TCRT) will report earnings on 2026-05-13.